CORT CORCEPT THERAPEUTICS INC revenue, earnings and financials

For the quarter ended June 30, 2026, CORCEPT THERAPEUTICS INC reported revenue of $256M (up 31.7% from a year earlier), net income of $43.0M and diluted EPS of $0.36; over the last four quarters revenue was $831M and net income $55.2M; for the fiscal year ended December 2025 revenue was $761M, up 12.8% on the year before.

CORT annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $761M, gross profit n/a, operating income $44.8M, net income $99.7M (margin 13.1%), EPS $0.82
• Fiscal year ended Dec 2024: revenue $675M, gross profit n/a, operating income $137M, net income $141M (margin 20.9%), EPS $1.23
• Fiscal year ended Dec 2023: revenue $482M, gross profit n/a, operating income $107M, net income $106M (margin 22.0%), EPS $0.94
• Fiscal year ended Dec 2022: revenue $402M, gross profit n/a, operating income $113M, net income $101M (margin 25.2%), EPS $0.87
• Fiscal year ended Dec 2021: revenue $366M, gross profit n/a, operating income $124M, net income $113M (margin 30.7%), EPS $0.89

CORT quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $256M (up 31.7% year over year), net income $43.0M, EPS $0.36
• Quarter ended Mar 31, 2026: revenue $165M (up 4.9% year over year), net income −$31.8M, EPS −$0.30
• Quarter ended Dec 31, 2025 (from the annual report): revenue $202M (up 11.1% year over year), net income $24.3M, EPS $0.20
• Quarter ended Sep 30, 2025: revenue $208M (up 13.7% year over year), net income $19.7M, EPS $0.16
• Quarter ended Jun 30, 2025: revenue $194M (up 18.7% year over year), net income $35.1M, EPS $0.29
• Quarter ended Mar 31, 2025: revenue $157M (up 7.1% year over year), net income $20.5M, EPS $0.17
• Quarter ended Dec 31, 2024 (from the annual report): revenue $182M (up 34.3% year over year), net income $30.7M, EPS $0.25
• Quarter ended Sep 30, 2024: revenue $183M (up 47.7% year over year), net income $47.2M, EPS $0.41
• Quarter ended Jun 30, 2024: revenue $164M (up 39.1% year over year), net income $35.5M, EPS $0.32
• Quarter ended Mar 31, 2024: revenue $147M (up 39.0% year over year), net income $27.8M, EPS $0.25
• Quarter ended Dec 31, 2023 (from the annual report): revenue $135M (up 31.4% year over year), net income $31.4M, EPS $0.27
• Quarter ended Sep 30, 2023: revenue $124M (up 21.5% year over year), net income $31.4M, EPS $0.28
• Quarter ended Jun 30, 2023: revenue $118M (up 13.9% year over year), net income $27.5M, EPS $0.25
• Quarter ended Mar 31, 2023: revenue $106M (up 12.8% year over year), net income $15.9M, EPS $0.14
• Quarter ended Dec 31, 2022 (from the annual report): revenue $103M (up 4.3% year over year), net income $16.6M, EPS $0.13
• Quarter ended Sep 30, 2022: revenue $102M (up 5.8% year over year), net income $34.6M, EPS $0.30
• Quarter ended Jun 30, 2022: revenue $103M (up 12.9% year over year), net income $27.4M, EPS $0.24
• Quarter ended Mar 31, 2022: revenue $93.7M (up 17.9% year over year), net income $22.8M, EPS $0.20
• Quarter ended Dec 31, 2021 (from the annual report): revenue $98.8M, net income $32.1M, EPS $0.26
• Quarter ended Sep 30, 2021: revenue $96.1M, net income $30.5M, EPS $0.24

CORT cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow $142M, share buybacks $173M
• Fiscal year ended Dec 2024: operating cash flow $198M, share buybacks $15.7M
• Fiscal year ended Dec 2023: operating cash flow $127M, share buybacks $0
• Fiscal year ended Dec 2022: operating cash flow $120M, share buybacks $0
• Fiscal year ended Dec 2021: operating cash flow $168M, share buybacks n/a

CORT balance sheet

• Jun 30, 2026: cash $111M, total assets $889M, total liabilities $183M, shareholders' equity $706M
• Mar 31, 2026: cash $109M, total assets $815M, total liabilities $177M, shareholders' equity $638M
• Dec 31, 2025: cash $120M, total assets $837M, total liabilities $189M, shareholders' equity $648M
• Sep 30, 2025: cash $125M, total assets $824M, total liabilities $192M, shareholders' equity $632M
• Jun 30, 2025: cash $103M, total assets $802M, total liabilities $166M, shareholders' equity $636M
• Mar 31, 2025: cash $89.8M, total assets $846M, total liabilities $163M, shareholders' equity $683M
• Dec 31, 2024: cash $128M, total assets $841M, total liabilities $161M, shareholders' equity $680M
• Sep 30, 2024: cash $137M, total assets $784M, total liabilities $145M, shareholders' equity $639M

What is CORT's revenue?

CORCEPT THERAPEUTICS INC reported $831M of revenue over its last four quarters, through June 30, 2026.

Is CORT profitable?

Yes. CORCEPT THERAPEUTICS INC earned $55.2M over the last four quarters.

What is CORT's EPS?

Diluted earnings per share over the last four quarters were $0.42; $0.36 in the latest quarter.

CORT ownership and insider trades · All stocks